Background: The Sencell sensor (Lifecare AS, Bergen, Norway) uses glucose induced changes in an osmotic pressure chamber for continuous measurement of glucose concentrations in the subcutaneous tissue. A close to linear correlation between the raw sensor signal and the glucose concentration and a very long duration of use (of up to 6-12 months or longer) are theoretically to be expected. The final device is planned to have the size of a grain of rice and to be implanted employing wireless energy and data transfer.

Method: For a first clinical proof of concept study in humans, a wired version of the core sensing technology was embedded into a 4 mm needle and inserted into the abdominal subcutaneous tissue of healthy volunteers. The study was conducted to collect first human proof-of-concept performance data for algorithm development during meal experiments and for further device optimization. The raw data was analyzed after one-point calibration and minor trend correction in comparison to the Statstrip blood glucose meter and the Freestyle Libre 2 glucose sensor.

Results: Seven participants (5 female, 2 male, age: 49±11 years) delivered a total of 105 direct comparator data-points (vs. Statstrip blood glucose meter) during repeated meal experiments with observation periods between 2 h and up to 72 days. The osmotic-pressure sensor followed glucose changes similar to the FreeStyle Libre device and reached an MARD of 9.8% in comparison to StatStrip (87 % and 13 % of the datapoints were lying in zones A and B of the consensus error grid, respectively).

Conclusions: In this first human proof-of-concept study, the osmotic-pressure based continuous glucose sensor was shown to track s.c. glucose concentrations in a comparable manner as the Libre 2 needle sensor. The clinical performance characteristics of the first wired prototypes provide an encouraging perspective for the upcoming next development steps.


A. Pfützner: Consultant; Novo Nordisk A/S, Research Support; LifeScan Diabetes Institute, Speaker's Bureau; AstraZeneca, Stock/Shareholder; Lifecare A/S, Diakard. M. Hanna: None. N. Thomé: None. H. Jensch: None.


Lifecare AS (LIFC-SEN-001)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at